BioMarin Pharmaceutical Inc. (LON:0HNC)

Market Cap	8.49B -12.4%
Revenue (ttm)	2.30B +12.4%
Net Income	387.16M +61.5%
EPS	1.99 +59.5%
Shares Out	n/a
PE Ratio	21.93
Forward PE	13.24
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,185
Average Volume	3,128
Open	59.00
Previous Close	60.14
Day's Range	54.25 - 61.09
52-Week Range	50.12 - 73.33
Beta	0.27
RSI	64.55
Earnings Date	Feb 20, 2026

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1996
• Employees: 3,040
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HNC

Financial Performance

In 2024, BioMarin Pharmaceutical's revenue was $2.85 billion, an increase of 17.97% compared to the previous year's $2.42 billion. Earnings were $426.86 million, an increase of 154.62%.

Financial numbers in USD